LIPOPOLYSACCHARIDE SUPPRESSES CYTOKINE RELEASE FROM COXSACKIE VIRUS-INFECTED HUMAN MONOCYTES

被引:17
作者
HENKE, A
SPENGLER, HP
STELZNER, A
NAIN, M
GEMSA, D
机构
[1] UNIV MARBURG,INST IMMUNOL,W-3550 MARBURG,GERMANY
[2] THURINGIAN INST MICROBIOL,DIV VIROL,JENA,GERMANY
来源
RESEARCH IN IMMUNOLOGY | 1992年 / 143卷 / 01期
关键词
MONOCYTE; COXSACKIE VIRUS-B3; CYTOKINE; IMMUNOSUPPRESSION; TNF-ALPHA; IL; 1-BETA; IL6; PROSTAGLANDIN-E2; LPS; CHRONIC MYOCARDITIS;
D O I
10.1016/0923-2494(92)80081-U
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infections by coxsackie virus B3 (CVB3) have been reported to be associated with an enhanced influx of mononuclear leukocytes into afflicted tissue. Current evidence indicates that monocytes/macrophages are specifically involved in CVB3-induced myocarditis by maintaining a chronic inflammatory response. To examine susceptibility and reactivity to CVB3, freshly isolated human monocytes were exposed to various virus doses (0.1-10 MOI) in the presence or absence of macrophage-activating lipopolysaccharide (LPS). CVB3 infection alone induced an activation of monocytes as evidenced by enhanced adherence, release of cytokines and secretion of prostaglandin E2 (PGE2). Simultaneous addition of LPS almost entirely suppressed LPS-specific production of tumour necrosis factor-alpha (TNF-alpha) and PGE2, partially inhibited release of interleukin 1-beta (IL 1-beta) and did not affect interleukin 6 (IL6) synthesis of CVB3-infected monocytes. These data show that CVB3 activates monocytes to cytokine production but renders them unreactive to further activating stimuli. Further studies should determine the extent to which continuous cytokine release from persistently CVB3-infected monocytes, and their apparent unresponsiveness to other stimuli, contribute to chronic myocarditis.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 24 条
[1]  
BENDINELLI M, 1988, COXSACKIEVIRUSES GEN, P81
[2]  
CHOW LH, 1988, NEW CONCEPTS VIRAL H, P205
[3]  
CONALDI PG, 1988, NEW CONCEPTS VIRAL H, P197
[4]  
DOHERTY DE, 1989, J IMMUNOL, V143, P3673
[5]  
GEMSA D, 1981, LYMPHOKINES, V4, P335
[6]  
GONG JH, 1991, IN PRESS J IMMUNOL
[7]  
HEIDENREICH S, 1988, J IMMUNOL, V140, P1511
[8]  
HUBER SA, 1984, AM J PATHOL, V116, P21
[9]  
HUBER SA, 1985, HERZ, V10, P10
[10]   MYOCARDITIS AND CARDIOMYOPATHY [J].
JAMES, TN .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (01) :39-41